Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Updated FIERCE-22 data: vofatamab with pembrolizumab for mUC

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the updated interim analysis of FIERCE-22 (NCT03123055). This trial is testing the exciting double immunotherapy combination of vofatamab with pembrolizumab in metastatic urothelial carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.